EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Assessment of potential predictive factors of dupilumab response in patients with moderate‐to‐severe atopic dermatitis

Gemma Melé-Ninot iD, Laia Curto-Barredo, Montserrat Bonfill-Ortí, Vicente Expósito-Serrano, Mónica Munera-Campos iD, Ignasi Figueras Nart, Constanza Riquelme-Mc Loughlin, Sara Gómez-Armayones, Jorge Spertino, Esther Serra-Baldrich

Australasian Journal of Dermatology · 2024-03 · 65 (2) · 153-162

DOI: 10.1111/ajd.14196 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Australasian Journal of Dermatology, online erschienen am 06.12.2023. Verfasst von Gemma Melé-Ninot und 9 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Hospital Universitari Sagrat Cor, Grupo Quirónsalud, Barcelona, Spain. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Eczema, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Registry of Atopic Dermatitis (REGAD).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dupilumab has shown to be an effective and safe treatment for patients with moderate‐to‐severe atopic dermatitis (AD).

Objective

To evaluate the predictive factors of response (PRF) in patients with moderate‐to‐severe AD treated with dupilumab.

Methods

Observational, retrospective and multicentre study conducted on adult patients diagnosed with moderate‐to‐severe AD treated with dupilumab, with a post‐treatment follow‐up of at least 16 weeks. The primary endpoints were EASI‐75 and the IGA scale at week 52.

Results

A total of 198 patients were included in the analysis. Mean age was 38 ± 15.1 years and 116 (58.6%) were men. The most prevalent AD‐predominant phenotypes were flexural eczema (45.3%), head‐and‐neck eczema (18.2%) and erythroderma (17.7%). At week 52, 140 (86.4%) patients achieved EASI‐75 and 119 (93.0%) achieved an improvement in ≥2 points from baseline in IGA score. Women were 3.6 times more likely to achieve EASI‐75 response than men (Odds ratio: 3.58; p = 0.020). While increased body mass index significantly reduced the probability of obtaining an improvement of ≥2 points in the IGA scale at week 52 (odds ratio: 0.88; p = 0.049).

Conclusions

Dupilumab was an effective treatment in patients with moderate‐to‐severe AD. Additionally, sex and body mass index were significantly associated with achieving EASI‐75 and an improvement of ≥2 points in the IGA scale, respectively, at week 52.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicEczemaAntibodies, Monoclonal, HumanizedAdultMaleHumansFemaleYoung AdultMiddle AgedRetrospective StudiesDouble-Blind MethodSeverity of Illness IndexTreatment OutcomeImmunoglobulin A

Stichwörter der Autor:innen

atopic dermatitisdupilumabpredictive factorstreatment

Substanzen

dupilumabImmunoglobulin AAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Dermatology Department, Hospital Universitari Sagrat Cor, Grupo Quirónsalud, Barcelona, Spain.
  • Dermatology Department, Hospital del Mar-Institut Mar d'Investigacions Mèdiques, Barcelona, Spain.
  • Dermatology Department, Hospital de Bellvitge, Barcelona, Spain.
  • Dermatology Department, Hospital Universitari Parc Taulí, Barcelona, Spain.
  • Dermatology Department, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Germans Trias i Pujol Research Institute (IGTP), Barcelona, Spain.
  • Dermatology Department, Hospital Clínic, Barcelona, Spain.

ORCID-Profile: Gemma Melé-Ninot, Mónica Munera-Campos

Förderung

  • Registry of Atopic Dermatitis (REGAD)

Zitieren

APA

Melé-Ninot, G., Curto-Barredo, L., Bonfill-Ortí, M., Expósito-Serrano, V., Munera-Campos, M., Figueras Nart, I., Riquelme-Mc Loughlin, C., Gómez-Armayones, S., Spertino, J., & Serra-Baldrich, E. (2024). Assessment of potential predictive factors of dupilumab response in patients with moderate‐to‐severe atopic dermatitis. Australasian Journal of Dermatology, 65(2), 153-162. https://doi.org/10.1111/ajd.14196

Vancouver

Melé-Ninot G, Curto-Barredo L, Bonfill-Ortí M, Expósito-Serrano V, Munera-Campos M, Figueras Nart I, et al. Assessment of potential predictive factors of dupilumab response in patients with moderate‐to‐severe atopic dermatitis. Australasian Journal of Dermatology. 2024;65(2):153-162. doi:10.1111/ajd.14196

BibTeX
@article{MelNinot2024,
  author = {Melé-Ninot, Gemma and Curto-Barredo, Laia and Bonfill-Ortí, Montserrat and Expósito-Serrano, Vicente and Munera-Campos, Mónica and Figueras Nart, Ignasi and Riquelme-Mc Loughlin, Constanza and Gómez-Armayones, Sara and Spertino, Jorge and Serra-Baldrich, Esther},
  title = {Assessment of potential predictive factors of dupilumab response in patients with moderate‐to‐severe atopic dermatitis},
  journal = {Australasian Journal of Dermatology},
  year = {2024},
  volume = {65},
  number = {2},
  pages = {153--162},
  doi = {10.1111/ajd.14196}
}
Kostenlos starten →